FDA approves Toujeo® Max SoloStar®
Bridgewater, New Jersey - March 27, 2018 – The U.S. Food and Drug Administration (FDA) approved Sanofi’s Toujeo® (insulin glargine 300 Units/mL) Max SoloStar® , the highest capacity long-acting insulin pen that will be available on the market.
The new Max SoloStar pen holds 900 Units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 Units/mL of Toujeo in a single injection.
Due to its higher capacity, Max SoloStar may reduce the number of pens adults prescribed Toujeo use, allowing for fewer refills and related copays, depending on the person’s insurance coverage. The maximum dose of up to 160 Units/mL may also help reduce the number of injections needed to deliver the required Toujeo dosage for some adults with diabetes.
Eligible commercially insured patients will pay a $0 copay if they are new to Toujeo for their first three prescription fills, and a $10 copay for their next 12 fills.
- Health & Medicine
- Men's Health
- Women's Health